Emergent BioSolutions Collaborates For Coronavirus Vaccine
Zacks Investment Research | Mar 10, 2020 10:27PM ET
Emergent BioSolutions Inc. (NYSE:EBS) announced that it has entered into a collaboration agreement with Novavax, Inc. (NASDAQ:NVAX) to support the latter’s development of a vaccine candidate to protect against coronavirus disease (COVID-19). Per the terms of the agreement, Emergent BioSolutions will use its contract development and manufacturing (“CDMO”) services to advance Novavax’s COVID-19 vaccine candidate into clinical stage.
Emergent BioSolutions is responsible for production of the vaccine candidate, which was developed using Novavax’s proprietary technology platform. Emergent BioSolutions has started preparations for this program and anticipates that the COVID-19 vaccine candidate can be used in a phase I study within next four months. Financial terms of the deal are yet to be disclosed.
Emergent BioSolutions offers CDMO services to several pharma and biotech companies as well as government agencies and non-government organizations. The company expects its past experience and broad countermeasure capabilities for emerging infectious diseases to support faster development of Novavax’s COVID-19 vaccine. Apart from CDMO services for such vaccines, the company is also focused on evaluating various vaccines and therapies to contain the risk of the deadly coronavirus.
In the past year, shares of Emergent BioSolutions have increased 1.7% against the article .
Several pharma/biotech companies are actively engaged in developing a vaccine for COVID-19 including Pfizer (NYSE:PFE) and J&J (NYSE:JNJ) . With the risk of global coronavirus outbreak rising, faster development of vaccines is the need of the hour. Although several companies are developing a cure, none of these vaccines are expected to be available before a year’s time. In this context, U.S. President Donald Trump encouraged executives to shorten the timelines for bringing a vaccine to market while keeping safety in mind. Trump urged pharmaceutical companies to collaborate to speed up work on developing a coronavirus vaccine.
Please note that accelerated development of COVID-19 vaccine will help save more lives across the globe. Moreover, it will also help to stop the onslaught of this virus on economic growth which seems to be slowly falling into a recession phase with supply and demand of various products getting affected.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.